All In Biotech

NDA 210326 · Fresenius Kabi USA

Fulvestrant

Fulvestrant · Intramuscular · Estrogen Receptor Antagonist

Last checked: Nov 19, 2026Latest source record: May 12, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

May 20, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

557

100 Phase 3, 120 recruiting

FAERS reports

17,216

15,760 serious, 2,840 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2024.

Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant Injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Mechanism: Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells. In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines. In in vivo tumor studies, fulvestrant delayed the establishment of tumors from xenografts...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 2021 Supplement 1 · Efficacy LetterLabel
  • May 20, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • FULVESTRANT · FULVESTRANT 250MG/5ML (50MG/ML) · SOLUTION, INTRAMUSCULAR · Prescription · TE AO

Clinical trials

Interventional ClinicalTrials.gov studies with "Fulvestrant" as an intervention, any sponsor and status, largest first.

All 557 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression2,842
  • fatigue1,865
  • neutropenia1,718
  • nausea1,598
  • metastases to bone1,493
  • death1,411
  • diarrhoea1,408
  • breast cancer metastatic1,259
  • metastases to liver1,226
  • neoplasm progression986
  • asthenia967
  • vomiting917

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200515
20069
20076
200820
20099
20108
201147
201240
201328
201435
2015120
2016254
2017483
2018699
20191,157
20202,013
20212,071
20222,058
20232,861
20241,970
20252,074
20261,237

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Aug 14, 2026

    Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fulvestrant (Fulvestrant)

2024 spending

$4.8M

Beneficiaries

1,139

6,934 claims

Per beneficiary

$4,212

$65.63 per unit

View as table
YearSpending
2020$3,669,405
2021$4,956,676
2022$6,875,649
2023$6,906,068
2024$4,797,792

Part B: Fulvestrant (Fulvestrant) · HCPCS J9394

2024 spending

$4.5M

Beneficiaries

2,044

6,980 claims

Per beneficiary

$2,205

2024 ASP limit $30.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$3,579,401
2024$4,506,277

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 386 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.